new manag multipl way win
price month
 close
ralinepag deliv out-performance etrasimod may
driver posit phase result ralinepag pulmonari arteri
hypertens pah reignit investor interest stock follow year
domin lacklust belviq obes commerci stori
believ well set-up catalyst-rich proof-of-concept
data etrasimod ulcer coliti key near-term readout
ralinepag potenti best-in-class profil expect oral
prostacyclin class becom multi-billion dollar class base project
uptak triple-therapi treatment pah ralinepag demonstr
promis efficaci phase trial even modest differenti
current market leader uptravi could translat opportun
global expect news flow final design phase
program though key phase data like event think
construct updat add valu investor refin program po
etrasimod provid plenti option etrasimod sever proof-
of-concept clinic readout throughout could pave way
target multipl indic phase data uc
provid initi insight program potenti valid mechan
action modul support expect success proof-of-
concept indic substanti upsid possibl believ
investor assign limit valu program
valuationiniti outperform rate target price
valuat base blend discount cash flow project
risk thesi includ clinic trial delays/failur ralinepag
etrasimod well lower-than-expected commerci uptak
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
arena biopharmaceut compani focus develop
novel small molecul drug optim receptor pharmacolog
diseas unmet need compani product candid
includ ralinepag pah etrasimod ulcer coliti
ralinepag success trial differenti
uptravi etrasimod demonstr efficaci uc/oth
indic increas po program
ralinepag po decreas etrasimod fail
demonstr efficaci uc/oth indic
 close
initi coverag outperform rate
target price new senior manag came on-board earli effect
focus develop pipelin asset target area high unmet need recent
phase ralinepag data pulmonari arteri hypertens pah show potenti best-in-
class qualiti oral prostacyclin class compos compani current
valu tp includ valu ralinepag final phase develop
plan ralinepag pend initi pivot readout may coupl year
meanwhil rest pipelin remain promis sever expect
catalyst featur proof-of-concept data etrasimod ulcer coliti uc
lead asset ralinepag readi expect broad phase program
could includ potenti studi establish clinic differenti market
leader jnj uptravi selexipag long term think oral prostacyclin class
potenti produc multi-billion dollar sale annual point commerci
preced pah market letairi vs tracleer suggest moder
differenti uptravi could enabl ralinepag captur close market share
possibl upsid despit project launch timelin year uptravi
among arena pipelin etrasimod promis asset multipl sourc
option favor efficaci data near-term uc phase could potenti pave
way support increas optim etrasimod expans indic target
high-value/highunmet-ne area includ primari biliari cholang expect
initi phase readout later year earli
credit suiss biotech short-term outlook though sever shot
goal near term expect investor focu etrasimod phase uc readout
key proof-of-concept event conserv valu program
tp pend clinic proof concept think market assign minim valu
current level especi consid evid support etrasimod class effect
credit suiss biotech long-term outlook pend elucid etrasimod
opportun anticip ralinepag remain primari base arena valuat
next coupl year expect establish low-risk reasonable-timelin clinic
plan along continu clinic front-lin oral prostacyclin triton studi
commerci success competitor jnj uptravi lead continu valu
build ralinepag asset ahead phase readout like event
regard etrasimod point numer nich diseas opportun
address high specif modul note achiev valu equal
current ralinepag assumpt possibl increment valu
asset point would equal valu compar
recepto garner acquisit celgen
credit suiss biotech outlook see arena highli attract
acquisit target base ralinepag phase outcom etrasimod develop
potenti hasten compani appeal larger pharma/biotech and/or provid
manag flexibl build multi-prong commercially-focus biopharma
pursu asset-specif partner retain full right asset intern
determin hold promis risk-adjust return potenti
ralinepag demonstr best-in-class preclin profil
signific pvr benefit impress improv exercis
capac activ arm phase drug look
best-in-class
ralinepag third approv drug class
best could becom distant number two uptravi market
oral prostacyclin may overestim consid drug
appear efficaci in-lin parenter deliveri
prostacyclin phase trial pah long-dat
investor patienc could test
believ efficaci data ralinepag compel potenti differenti class preced
second-in-class drug moder improv profil take signific market share pah success triton
studi could expand use oral prostacyclin earlier diseas cours support multi-billion dollar opportun class
etrasimod potenti util multipl indic
new manag team maxim valu asset
long-term ulcer coliti competit commerci
drug unclear differenti celgen ozanimod
requir phase program would expens challeng
execut commerci opportun indic less
clear arena may better partner asset
see potenti etrasimod multipl indic think investor requir convinc proof-of-concept data assign
signific valu etrasimod earli preclin profil look promis optimist favor phase outcom
uc await updat manag view optim valu creation path go forward asset
arena find uniqu applic earlier-stag asset
multipl shot goal etrasimod well-trod uc
uniqu indic pg pbc potenti upsid
attract risk-reward opportun wholly-own
pain associ crohn diseas
arena asset mainli second-in-class unclear
differenti exist product much relianc
around argument preclin profil clinic data
need believ pipelin produc multipl uniqu
new manag seem unafraid pursu creativ aggress develop approach drive valu creation
pipelin asset expect manag identifi effici path forward program posit proof-of-concept seek partner
program fit within arena long-term commerci area focu
sale miss expectationsposit ph ralinepag data paheisai new market initi belviqcatalysttimingkey investor focu eventsetrasimod uc phase phase pain crohn diseas phase pbc phase pg phase data-nelotanserin rem phase data pahetrasimod ucetrasimod pgetrasimod pain charl martineau pm univers toronto
ralinepag promis clinic profil pah
potenti differenti
ralinepag demonstr posit differenti vitro profil versu uptravi
selexipag current standard bearer among oral prostacyclin agonist
phase ralinepag clinic data heavili pre-treat popul enrol trial
arguabl best-in-class among oral prostacyclin agonist
phase trial design pend arena seek path optim time
market incorpor long-term plan ensur ultim label highli
develop ralinepag oral prostacyclin receptor agonist
treatment pah believ ralinepag well posit captur larg market
share rapidli expand multi-billion dollar potenti oral prostacyclin market
segment given strong phase profil attract pharmacokinet potenti
translat best-in-class preclin profil promis clinic
compani ran sever preclin assay ralinepag versu selexipag
activ metabolit demonstr better vitro characterist includ
reduct vasoconstrict
inhibit smooth muscl cell growth
inhibit platelet aggreg
ralinepag also shown greater potenc measur camp activ selexipag
agent longer half-lif selexipag allow dose regimen
reduc peak-to-trough ratio produc pk profil closer
continu dose iv/sc prostacyclin potenti lead improv clinic
result term efficaci and/or toler
promis phase result strong efficaci signal
arena conduct phase trial compar ralinepag twice-daili versu placebo pah
patient mono dual background therapi studi enrol patient
random ralinepag pbo follow treatment period week
dose titrat follow week stabl dose studi on-going open-label
patient baselin characterist show ralinepag phase enrol pre-treat
aggress manag patient patient enrol ralinepag arm
dual-background therapi versu placebo arm higher number patient
placebo arm recent start pah therapi within six month trial start
may influenc placebo group minut walk result
studi achiev primari endpoint chang baselin pulmonari vascular
resist pvr versu placebo top-line result studi summar
treatment ralinepag led signific improv pvr versu placebo
meaning increas ralinepag arm increas seen
ralinepag arm clinic meaning signific consid level
pre-treat patient enrol trial comparison uptravi produc
increas activ arm phase trial fewer patient dual
figur improv baselin activ arm combo trial
credit suiss adapt chakinala murali robyn barst short-term benefit long-term outcom evolut
clinic trial pulmonari arteri hypertens pulmonari circul
ralinepagplacebotreat effectchang pvr chang absolut chang baselin pvr absolut chang baselin pvr geometr mean ratio pvr pulmonari vascular resist minut walk charl martineau pm univers toronto figur comparison ralinepag phase across oral prostacyclin clinic trial
safeti profil drug gener consist prostacyclin therapi
includ typic prostanoid side effect headach nausea diarrhea jaw pain
flush frequent titrat period seriou advers event
occur patient take ralinepag patient placebo
discontinu rate due advers event safeti assess period
patient take ralinepag versu take placebo suggest good
phase program balanc time-to-market broad label
base profil develop date believ pvr reduct produc ralinepag
convinc portend highli efficaci agent note arena phase
program may includ function endpoint explicitli studi phase long-
term studi like evalu drug efficaci clinic outcom
drug effect realli doubt safeti profil ralinepag class
accept phase trial pah lengthi conduct patient pah
typic heavili pre-treat one two background therapi may
modestli higher usual risk set model po program
current may elev assumpt closer standard po phase
trial full plan articul reflect high confid ralinepag oral
expect announc phase trial design manag
indic pursu broad program includ sever studi eye toward
optim ralinepag time market fulli develop highli competit profil includ
studi long-term outcom possibl head-to-head comparison uptravi
believ trial investig function endpoint cpet
cardiopulmonari exercis test walk distanc could success
limit sampl size estim patient may enabl establish
efficaci pursu initi regulatori approv given greatest benefit outcomes-
base trial pah usual seen first six month also possibl ralinepag
demonstr benefit compon typic clinic worsen composit
hospit diseas progress decreas baselin howev
unlik abl demonstr statist signific benefit
outcom shorter smaller trial larger perhap patient outcom trial
would like pursu parallel support long-term label
arena also develop extend releas version ralinepag allow once-daili
dose new formul half-lif auc lower cmax
iv-lik profil could translat addit clinic benefit yet
confirm suspect compani may seek incorpor once-daili product
function baselin effect vs pbo baselin mean pvr geometr mean effect vs pbo phase phase week charl martineau pm univers toronto
robust carri multi-billion dollar potenti
oral agent expand prostacyclin class class frame
magnitud potenti upsid
uptravi griphon trial support combin use oral prostacyclin therapi
triton may posit oral prostacyclin part front-lin combin regimen
ralinepag posit demonstr differenti approv agent
oral prostacyclin class
introduct
growth
second-to-market uptravi actelion class recent report
annual sale run-rat million uptak driven increas eas use
oral agent compar inhal infus prostacyclin altern oral
prostacyclin alreadi repres total prostacyclin market sale
fourth year oral agent avail prostacyclin oldest approv class
year market treat pah continu view gold-standard
figur oral prostacyclin agent ww sale figur oral agent prostacyclin class
expect patient continu requir infus prostacyclin therapi
opportun exist first time posit therapeut class major
clinician consid potent closer front-lin set sever year ago
ambit studi prove benefit aggress front-lin treatment approach
use combin oral therapi case endothelin receptor antagonist
current sponsor triton studi explor
benefit tripl oral combin front-lin set
prostacyclin uptravi compar dual-combin therapi expect result
studi
expect continu rapid growth among oral prostacyclin class uptravi
captur lion share near term look market comp note
class annual global sale us sale compar oral
prostacyclin class carri higher price point annual vs era
market opportun off-set avail fine titrat infus
prostacyclin continu
late-stage/progress patient still success outcom triton would lead
expand penetr oral prostacyclin earlier use lead improv
therapeut durabl suggest market opportun within reach class
view essenti
interestingli market exampl also support valu ralinepag
illustr exampl success letairi gilead came market six
year market pioneer tracleer actelion letairi offer
differenti tracleer patient form vs pill
lack black box warn liver monitor eventu grew captur
us market note letairi develop myogen acquir gilead
year prior fda approv
multipl differenti point possibl ralinepag
see sever factor could influenc rel market uptak ultim valu
ralinepag franchis
efficaci
term efficaci see ralinepag phase data roughli compar uptravi
base favor pharmacokinet drug think possibl ralinepag
demonstr differenti profil across phase program administr
previous highlight potenti dose xr formul
could provid ralinepag dose advantag highlight
potenti
pharmacokinet advantag ralinepag oral prostacyclin also expect
arena consid evalu ralinepag directli selexipag fashion part
phase program though clear comparison would limit pvr-type
endpoint includ function outcom well
near-term potenti pivot point ralinepag valu could unit
freedom-ev trial expect read orenitram limit
commerci success despit launch ahead uptravi due perceiv toler
issu limit efficaci claim label freedom-ev studi design
establish orenitram efficaci combin set even posit data
consult expect signific increas prescript given on-going titrat
toler challeng drug still posit outcom would least sustain
orenitram abil hold market share ralinepag success would thu creat
three-way market segment trial read neg mix efficaci
pictur see trial po slightli coin flip believ orenitram could
cede market share uptravi competit benefit ralinepag increas
arena appeal potenti target becom clearer oral prostacyclin
market may exist long-term two-way market
revenu build base case make follow assumpt
market entri us eu
us price gross price us grow roughli line
expect price uptravi
eu price us price base similar comp pah space
complianc expect complianc line estim oral
agent indic
sale model global us
base case assumpt includ phase program produc
point differenti arriv seven-year post-approv market share
ralinepag us eu within oral prostacyclin
competit market assumpt includ mix result best
orenitram freedom-ev trial success triton
studi uptravi
model durat model ralinepag sale termin valu
project gradual share loss potenti gener uptravi launch project
total ralinepag patient diagnos patient oral prostacyclin patient shareyr peakralinepag market lossuptravi market share oral treat price price revenu patient diagnos patient oral prostacyclin patient shareyr peakralinepag market lossuptravi market share oral treat price price revenu charl martineau pm univers toronto
etrasimod modul uniqu profil offer
auto-immune/inflammatori
class demonstr efficaci across sever autoimmun indic
second-gener agent like celg ozanimod arna etrasimod
select possibl reduc allow broader rang target indic
etrasimod preclin profil suggest potenti differenti
celg ozanimod establish efficaci uc etrasimod initi proof-of-concept
indic data expect
etrasimod oral receptor modul studi ulcer coliti uc
addit indic t-cell mediat inflamm implic
on-going phase trial moderate/sever uc expect readout base
data ozanimod optimist etrasimod mechan action like
demonstr efficaci trial primari endpoint compani also conduct
proof-of-concept studi patient pyoderma gangrenosum pg primari biliari
etrasimod select modul may lead fewer
receptor subtyp link immunolog function
immun cell traffick immun surveil endotheli barrier integr
figur physiolog function receptor subtyp base preclin studi
nielsen ole haagen et al signal inflammatori bowel diseas trend molecular medicin
bind modul receptor may block gradient-depend
egress lymphocyt lymph node decreas level circul lymphocyt
possibl reduc inflammatori respons
first-gener agent target receptor fingolimod gilenya less
select target receptor subtyp product util
somewhat limit result drug safeti profil includ advers event
bradycardia elev liver enzym impair pulmonari function
barrier function angiogenesi heart rate controlendotheli barrier function modul vascular toneendotheli barrier function vasoconstrict heart rate control may promot vasorelax indirectlyvasoconstriction-immunelymphocyt egress lymphoid organ suppress treg cell polar follicular posit cellsposit immatur cell progenitor within bone marrowlymphoid tissu express modul dendrit cell cell differentiationnatur killer cell migrationnervousneur cell function migration-neur cell function charl martineau pm univers toronto
second-gener agent current develop etrasimod celgen
ozanimod select affin target subset receptor approach
expect result fewer less sever advers event etrasimod target
receptor avoid receptor may associ
cardiac pulmonari toxic
preclin studi etrasimod shown well toler meaning
chang heart rate mean arteri pressur bodi temperatur anim model
wide safeti margin rel therapeut human dose
phase dose escal studi healthi volunt demonstr
etrasimod well toler dose mg
mild dose-respons report
dose-depend sustain decreas lymphocyt count consist
mechan action
lymphocyt count return baselin discontinu
etrasimod quick onset action led reduct lymphocyt count day
cohort return within baselin seven day
discontinu refer phase studi ozanimod led
lymphocyt count reduct day dose recoveri roughli within
baselin seven day discontinu tran et
figur etrasimod produc robust mean lymphocyt reduct
three subject develop first-degre atrioventricular block one placebo arm one
cohort patient experienc liver enzym elev greater
modest chang heart rate observ dose level
result suggest potenti amen safeti profil potenti differenti
ulcer coliti data
arena initi phase trial etrasimod uc studi enrol
patient moderate/sever uc subject mayo score includ endoscop
sub-scor rectal bleed score
efficaci endpoint evalu week treatment includ improv
mayo clinic score total respons remiss rate mucos
heal versu placebo dose respons also assess long-term safeti
support open-label extens
studi primari endpoint partial three-compon mayo score includ
rectal bleed stool frequenc endoscop measur wherea typic
partial mayo score includ non-invas compon stool frequenc rectal
bleed physician global assess consult indic arena
methodolog clinic meaning endpoint sinc endoscop measur like
object physician global assess
proof efficaci lymphocyt reduct phase improv probabl
etrasimod success develop across rang indic arena two
addit phase studi pyoderma gangrenosum pg primari biliari cholang
ozanimod valid modul efficaci uc
celgen ozanimod receptor modul also target receptor
valid class effect uc touchston trial studi
enrol uc patient placebo-control trial evalu ozanimod efficaci
induct phase week mainten period week induct
patient take ozanimod achiev clinic remiss eight week defin
mayo score point individu subscor versu placebo arm
number increas week placebo remain consult
believ encourag result clinic meaning note
ozanimod oral dose advantag compar anti-tnf therapi
demonstr roughli compar data studi
sandborn william et al ozanimod induct mainten treatment
ulcer coliti new england journal medicin credit suiss
sandborn william et al ozanimod induct mainten treatment
ulcer coliti new england journal medicin credit suiss
figur clinic remiss rate ulcer coliti
fda approv label tofacinitib octav trial sandborn william et al ozanimod induct mainten treatment
ulcer coliti new england journal medicin credit suiss
entir compar expect data etrasimod studi given
differ compon partial mayo score data ozanimod phase
tofacitinib phase studi suggest earli point improv versu placebo
partial mayo may portend clinic remiss benefit versu placebo
sandborn william et al ozanimod induct mainten treatment ulcer coliti new england journal medicin
sandborn william et al tofacitinib induct mainten therapi ulcer coliti new england journal medicin
ozanimod gener well toler phase studi one patient
cohort first degre atrioventricular block sinu bradycardia patient
cohort absolut lymphocyt count lower limit normal
patient enrol placebo-control portion phase studi
particip open-label expans studi evalu long-term efficaci safeti
week patient evalu efficaci littl activ diseas base
physician global assess littl blood stool
blood stool safeti profil extens similar initi
portion studi accord celgen
market potenti uc promis highli competit
cdc estim patient suffer uc us
consid moderate/sever initi treatment option mesalamin
prednison offer limit efficaci often lead remiss subset patient
refractori patient may receiv immunosuppress therapi and/or anti-tnf
costli carri addit side effect present addit treatment hurdl
anti-tnf requir subcutan intraven deliveri
consult emphas strong patient prefer oral agent treatment
uc depend efficaci safeti new oral agent may even move ahead
anti-tnf treatment paradigm abl address less sever patient given
administr conveni potenti lower cost
among drug current develop uc modul jak inhibitor
promis oral agent xeljanz jak inhibitor recent demonstr
efficaci uc remiss rate activ arm two phase
trial howev rate infect herp zoster infect higher activ
arm xeljanz also associ increas lipid level subject take
drug cardiovascular event versu none take placebo phase studi
larg expect efficaci class modul jaki physician
indic safeti crucial determin product adopt suggest
possibl advantag modul believ ampl opportun multipl
new player consid market size price assumpt
calcul total opportun uc novel agent approxim us
difficulti establish efficaci increasingli refractori popul led uc trial
becom larger time consid larg number program develop
enrol highli competit base phase outcom etrasimod arena
manag next determin best cours forward uc partnership go-
alon strategi expect data-driven decis consider made
avail intern resourc
drug candidatecompanyphasemoleculerout administrationetrolizumabroch hold agiiimonoclon antibodyiv iiismal moleculeoralozanimodcelgen corporationiiismal moleculeoralstelarajohnson johnsoniiimonoclon antibodyiv inc iibsmal inc iibsmal inc iibpeptideoralfilgotinibgilead scienc inc ii/iiismal pharma inc iismal inc iismal moleculeoralbertilimumabimmun ltd iimonoclon squibb companyiimonoclon antibodyivbrilacidininnov inc iismal moleculeiv oral co ltd iismal moleculeoraletrasimodarena inc iismal moleculeoralg corporationiiantisenseoralg pharma ltd iismal nviismal plciismal plciismal moleculeiv hakko kirin co ltd iimonoclon corporationiismal moleculeoralmirikizumab lilli companyiimonoclon antibodyiv scotezlacelgen corporationiismal inc iinot specifiediv inc iiproteinor scrisankizumababbvi inc iimonoclon antibodyiv biolog gmbh co kgiiother nucleic group plciimonoclon antibodyiv scupadacitinibabbvi inc iismal charl martineau pm univers toronto
condit
addit auto-immun
etrasimod may effect sever addit indic
arena highlight possibl applic modul high-potenti
indic indic offer commerci opportun
realm uc also far less competit approv
smaller indic could provid substanti upsid arena may
manag compani could conduct phase studi multipl indic
multipl product beyond
compani explor etrasimod efficaci across two on-going phase trial
pyoderma gangrenosum pg one common extraintestin complic
inflammatori bowel diseas pg neutrophil dermatosi may occur
independ associ varieti system diseas approxim
pg patient also affect associ system diseas
treatment pg associ underli crohn uc usual reli agent
effect ibd treat underli diseas possibl address
extraintestinal/skin manifest therefor believ etrasimod potenti address
major patient may heavili influenc perceiv efficaci uc
pbc fairli rare condit affect predominantli woman report preval
estim rang case per preval us among
highest report patient asymptomat diagnosi common
symptom fatigu pruritu pbc progress sever complic may
aris diseas cirrhosi hepatocellular carcinoma osteoporosi
pbc patient recommend chronic therapi ursodeoxychol acid udca
shown improv liver function modifi natur diseas cours possibl
avoid delay liver transplant ocaliva intercept also approv treatment
pbc combin udca inadequ respond altern
patient dont respond udca monotherapi combo ocaliva
arena enrol patient inadequ respons udca phase studi
similar patient popul target ocaliva refer intercept project initi
launch focu patient us ocaliva pbc
ocaliva phase trial enrol patient inadequ respons unabl
toler udca key efficaci endpoint decreas alkalin phosphatas
total bilirubin level trial durat month trial set preced
potenti quick approv path base rel small trial evalu surrog
explor pain associ crohn
full agonist receptor current explor
treatment abdomin pain subject crohn diseas data expect
receptor distribut enter nervou system gi tract also
express inflammatory/immun cell exact mechan still unclear
preclin model suggest receptor agonist might analges effect
compani believ high select may decreas off-target activ
given express pattern receptor preclin evid
could efficaci treat viscer pain
compani estim ibd patient experi persist symptom
includ pain assum major case relat viscer pain
commerci opportun might signific proof-of-concept efficaci need
investor assign valu asset
arena elig receiv aggreg develop regulatori
mileston axov well sale mileston undisclos purchas price
adjust payment base axov net sale nelotanserin
nelotanserin highli select invers agonist current studi phase
trial lewi bodi dementia one patient visual hallucin
rem sleep behavior disord initi studi miss statist signific
efficaci endpoint demonstr posit trend motor improv subset
subject axov discuss larger trial fda rem studi expect
report data axov estim patient lewi bodi dementia
us experi neuropsychiatr symptom includ visual
hallucin patient experi rem sleep behavior disord
compani also receiv royalti rang product suppli
purchas revenu relat sale belviq licens eisai weight loss drug
arriv target price use blend valuat approach includ product-
base dcf dcf
dcf model assum discount rate standard discount rate late-stag
pre-commerci compani fulli dilut share million tax rate
carri project assign termin valu assign per share
valu account etrasimod pipeline/partn asset
current model etrasimod base peak sale po
tbd indic expect refin project develop path
forward asset indication-specif potenti becom clearer
detail dcf compon includ follow
second valuat scenario driven highli efficient/m model
support target reflect sg synergi
tax rate increas revenu
probabl success
standard probabl success assumpt phase asset
phase asset phase asset asset nda/bla stage
slight adjust base histor probabl success specif diseas
assign po ralinepag given uncertainti relat phase design
potenti approv base exercis capac endpoint would expect re-evalu
po assumpt phase program design solidifi note
increas po could lead valuat increas program
arena net cash estim suffici fund
oper project cash flow oper
blue sky valuat base ralinepag success trial
differenti uptravi etrasimod demonstr efficaci uc/oth
indic increas po program grey sky valuat
base ralinepag po decreas etrasimod fail
demonstr efficaci uc/oth indic
poorly-design studi inadequ endpoint enough power neg
safety/efficaci signal neg dsmb/health author rule specif
includ
ralinepag phase failur pah lack differenti uptravi
success freedom-ev result orenitram
failur triton trial earli triple-therapi
negative/mix result etrasimod ulcer coliti indic
failur pipeline/partn asset
manufacturing/suppli risk includ limit suppli disrupt product
batch adher
contamin technic difficulti produc function complex molecul delay
construction/certif new facil inadequ lack materi
qualiti standard manufactur shutdown due
inabl suppli enough materi clinic trial inabl meet commerci
commerci risk includ limit lower-than-expect adopt drug
target popul competit clinical/exist agent payer-impos access
fewer patient start use oral prostacyclin
lower-than-expect adopt ralinepag versu uptravi orenitram
pricing/reimburs pressur ralinepag and/or etrasimod
smaller project patient popul addit indic explor
etrasimod
incom statement million except incom incom lncome net loss/shar share share sheetal cash current asset portion lt portion defer current total current lt total stock/oth equiti total sharehold liabil sharehold charl martineau pm univers toronto
flowal incom stock base comp depreci chang oper assets/li prepaid expens accru exp net cash use oper fix fix invest net cash use invest issuanc debt/conv issuanc pref issuanc common exercis stock financ net cash provid financ exchang increas decreas begin end charl martineau pm univers toronto
compani mention price
